{"prompt": "['aim', 'TM', 'mune', 'THERAPEUTICS', 'A Nestl\u00e9 Health Science Company', 'CLINICAL STUDY PROTOCOL', 'ARC009', 'Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in', 'Children and Adolescents: Real-World, Open-Label, Quality of Life Study', 'Protocol Amendment 1.0 - 11 Apr 2018', 'Reference Numbers: NCT03703791, EudraCT 2018-000326-58', 'Aimmune Therapeutics, Inc.', '8000 Marina Blvd, Suite 300', 'Brisbane, CA 94005', 'United States']['Aimmune Therapeutics, Inc.', 'CLINICAL STUDY PROTOCOL', 'Protocol Title:', 'Peanut Allergy Oral Immunotherapy Study of AR101', 'for Desensitization in Children and Adolescents:', 'Real-World, Open-Label, Quality of Life Study', 'Protocol Identifier:', 'ARC009', 'Phase:', '3b', 'Investigational Product:', 'AR101', 'Sponsor:', 'Aimmune Therapeutics, Inc.', '8000 Marina Blvd, Suite 300', 'Brisbane, CA 94005', 'United States', 'Reference Number:', 'EudraCT 2018-000326-58', 'Sponsor Medical Monitor: Stuart McIntosh, BM BS, MRCS, MD, FFPM', 'Mobile:', '+44 7825 904 651', 'Email:', 'smcintosh@aimmune.com', 'Original Protocol:', '0.0 - 03 Apr 2018', 'Amendments', 'Global:', '1.0 - 11 Apr 2018', 'This study will be conducted according to the Declaration of Helsinki (2013), principles of Good Clinical', 'Practice as described in International Council for Harmonisation guidelines, including the archiving of', 'essential documents, EU Directive 2001/20/EC (the Clinical Trials Regulation), EU Directive', '2005/28/EC (Good Clinical Practice Directive), and local applicable legislation including but not limited', 'to the UK SI 2004/1031 Medicines for Human Use (Clinical Trials) Regulations 2004 as amended.', 'Confidentiality Statement', 'The information contained in this document and all information provided to you related to AR101 are the', 'confidential and proprietary information of Aimmune Therapeutics, Inc. (\"Aimmune\"; Aimmune', 'Confidential Information) and except as may be required by federal, state, or local laws or regulations,', 'may not be disclosed to others without prior written permission of Aimmune. However, the investigator', 'may disclose such information to supervised individuals working on AR101, provided such individuals', 'agree to be bound to maintain the confidentiality of such information.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 2 of 122', 'SYNOPSIS', 'Title of Study: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and', 'Adolescents: Real-World, Open-Label, Quality of Life Study', 'Short Title: AR101 Health-Related Quality of Life (HRQOL) Study in Peanut-Allergic Subjects', 'Protocol Identifier: ARC009', 'EudraCT: 2018-000326-58', 'Phase of Development: 3b', 'Number of Subjects: Approximately 200', 'Study Centers: Approximately 45 in Europe', 'Purpose of the Study: To compare the HRQOL of AR101 characterized oral desensitization', 'immunotherapy (CODITT) in combination with standard of care (peanut avoidance, education) versus', 'standard of care alone in peanut-allergic subjects aged 4 to 17 years, inclusive. The HRQOL of', 'parents/caregivers will also be assessed.', 'Study Objectives:', 'Primary:', 'To assess proxy- and self-reported disease-specific HRQOL of peanut-allergic subjects aged 4 to', '17 years, inclusive, receiving AR101 in combination with standard of care versus standard of care', 'alone for approximately 18 months', 'Secondary:', 'Safety and tolerability of AR101', 'To characterize changes over the course of the study in the following:', 'Disease-specific HRQOL of parents/caregivers', 'Relationship between clinical efficacy of AR101 (change in level of sensitization to peanut allergen)', 'and HRQOL of subjects and parents/caregivers', 'Exploratory:', 'To assess the following:', 'Self-reported assessments of control and confidence; reassurance, worry, and severity of allergic', 'reactions based on food challenge outcomes; and overall HRQOL', 'Changes in nondisease-specific measures of HRQOL, anxiety, and depression in subjects and', 'parents/caregivers', 'Health state utility estimates for economic analysis', 'Changes in peanut skin prick test (SPT) mean wheal diameters associated with AR101 treatment', 'Changes in control of pre-existing concomitant atopic disease (asthma, allergic rhinitis, atopic', 'dermatitis)', 'Relationship between basophil activation, clinical efficacy of AR101, and changes in HRQOL', 'AR101 treatment experience among subjects and parents/caregivers', 'Study Design:', 'This is a phase 3b, randomized, open-label, European study of the HRQOL of AR101 in combination with', 'standard of care (AR101 herein) compared with standard of care alone in approximately 200 peanut-allergic', 'subjects aged 4 to 17 years, inclusive. Standard of care includes avoidance of peanuts/peanut-containing', 'foods, and education on recognition and management of allergy symptoms and appropriate use of rescue', 'medications (eg, epinephrine auto-injectors). HRQOL of parents/caregivers will also be assessed. The', 'safety and tolerability of AR101 will be evaluated.', 'Eligible subjects will be randomly assigned 2:1 to AR101 treatment or standard of care alone.', 'Randomization will be stratified by age group (4-12 years and 13-17 years). Subjects in both treatment']\n\n###\n\n", "completion": "END"}